Niagen Bioscience
NAGE
53 hedge funds and large institutions have $16.5M invested in Niagen Bioscience in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 7 closing their positions.
383% more call options, than puts
Call options by funds: $87K | Put options by funds: $18K
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
1% more capital invested
Capital invested by funds: $16.4M → $16.5M (+$174K)
0.46% more ownership
Funds ownership: 14.95% → 15.41% (+0.46%)
2% less funds holding
Funds holding: 54 → 53 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$643K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$166K |
| 3 |
Jane Street
New York
|
+$61K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$48K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$46.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$433K |
| 2 |
Millennium Management
New York
|
-$147K |
| 3 |
CCM
Cox Capital Management
Andover,
Massachusetts
|
-$136K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$17.6K |
| 5 |
Two Sigma Investments
New York
|
-$16.3K |
NAGE Hedge Fund Activity: Q4 2023 in Review
53 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2023, worth a combined $16.5M — up 1.1% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NAGE and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 18 added.
The largest buyer was Tieton Capital Management, adding an estimated $643K. The largest seller was GMT Capital, exiting entirely with an estimated $433K sold.
- 53 institutional investors held Niagen Bioscience (NAGE) as of Q4 2023, down from 54 in Q3 2023.
- Funds reported $16.5M of Niagen Bioscience stock for Q4 2023, up 1.1% quarter-over-quarter.
- 6 funds opened new Niagen Bioscience positions in Q4 2023 and 7 closed out, a net change of -1 holder.
- The largest Niagen Bioscience buyer in Q4 2023 was Tieton Capital Management, an estimated $643K added.
- The largest Niagen Bioscience seller in Q4 2023 was GMT Capital, an estimated $433K sold.
Based on aggregated 13F filings for Q4 2023.